ACADIA Pharmaceuticals : R&D Day Presentation

Published: 2025-06-25 08:52:11 ET ACAD

Published on 06/25/2025 at 08:52

Advancing Care for Underserved

Neurological and Rare

Diseases

RCD Day • New York City

June 25, 2025

CEO

Opening Remarks

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all

statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates,"

"believes," "estimates," "projects," "predicts," "outlook," "potential" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this presentation, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products and our product candidates, and for trofinetide in jurisdictions outside the U.S. and Canada, including Europe; (iv) estimates regarding the prevalence of the diseases targeted by our products and product candidates; (v) potential markets for any of our commercial products or product candidates; and (vi) our estimates regarding our future financial performance, cash position, profitability or capital requirements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause o ur actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to successfully develop our product candidates and to obtain necessary regulatory approvals for our product candidates and, if and when approved, mar ket acceptance of our products; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2024 as well as our subsequent filings with the Securities and Exchange Commission from time to time, including our quarterly report on Form 10-Q for the period ended March 31, 2025. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Projections, assumptions and estimates of the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.

ACP-101 (P3-PWS)

Data expected early Q4 2025

ACP-204 (P2-ADP)

Data expected mid-2026

expected in 2025

expected in 2025 for

Prader-Willi Syndrome

to invest aggressively in pipeline

developments

Advancing Care for Underserved Neurological and Rare Diseases

PRECISION MEDICINE | DATA INNOVATION | GLOBALIZATION | PATIENT EMPO WERMENT

CORE FRANCHISE CORE PIPELINE EXPANSION AREAS

Neuro Psych

Neuro Rare

ADP

ACP-204

(new 5-HT2A inverse

agonist)

LBDP

ACP-204

(new 5-HT2A inverse

agonist)

PWS

ACP-101

(Intranasal Carbetocin)

Rett/Fragile X

ACP-2591

(cGP analogue)

Essential Tremor

ACP-711

(selective GABAA-α3 modulator)

MDD

ACP-211

(Deuterated R-norketamine)

TD/HD

ACP-271

(GPR88 agonist)

Expansion to other Rare Disease areas under evaluation

Endocrine Metabolic Nephrology Cardiovascular Immunology

Expanded pipeline via

internal

innovation and

business development

PRECISION MEDICINE | DATA INNOVATION | GLOBALIZATION | PATIENT EMPO WERMENT

Disclaimer

ACADIA Pharmaceuticals Inc. published this content on June 25, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 25, 2025 at 12:51 UTC.